Pfizer’s decision Wednesday to pull its sickle cell pill off the market because of safety concerns shocked advocates and doctors, leaving many searching for answers and scrambling for ways to ...

This article is part of “Innovations In: Sickle Cell Disease,” an editorially independent special report that was produced with financial support from Vertex Pharmaceuticals. Kalpna Gupta was ...

Sep. 12, 2024 — Researchers have found that being a carrier for sickle cell disease, known as having sickle cell trait, increases the risk of blood clots, a risk that is the same among diverse ...

Pfizer will voluntarily pull its sickle cell disease (SCD) drug Oxbryta from all markets worldwide, a major blow to a $5.4 billion acquisition the New York pharma made two years ago. Pfizer will ...

Pfizer PFE3.46%increase; green up pointing triangle said it is voluntarily withdrawing all lots of its sickle-cell drug Oxbryta in all markets where it is approved, two years after acquiring its ...

Sickle cell disease (SCD) is an inherited health condition that slows the flow of red blood cells in your body. For people with SCD, hemoglobin S (a mutated protein that transports oxygen) causes ...

Sept 26 (Reuters) - U.S. drugmaker Pfizer (PFE.N), opens new tab said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where it is approved, citing risks ...

September Is Sickle Cell Awareness Month. While many people are familiar with sickle cell anemia, sickle cell traits have also plagued our community. Sickle cell trait (SCT) is an inherited blood ...

Sickle cell disease (SCD) is an inherited disorder that affects over 100,000 people in the United States, according to the Sickle Cell Disease Association of America, of that number, the Centers ...

Pfizer’s startling announcement late Wednesday that it would pull its pill for sickle-cell disease off pharmacy shelves is a ...

Sept 26 (Reuters) - Pfizer's (PFE.N), opens new tab decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed up trials of new experimental ...

Conducted as part of the Sickle Cell Disease Implementation Consortium (SCDIC), the study included 2,282 individuals ages 15–45 years, with sickle cell disease. About 500 (22%) had HbSC.